Research programme: heat-activated liposome encapsulated cancer therapeutics - Celsion Corporation

Drug Profile

Research programme: heat-activated liposome encapsulated cancer therapeutics - Celsion Corporation

Alternative Names: Liposomal carboplatin; Liposomal docetaxel

Latest Information Update: 06 Sep 2010

Price : $50

At a glance

  • Originator Celsion Corporation
  • Developer Celsion Corporation; Duke University Medical Center
  • Class Platinum complexes; Small molecules; Taxanes
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 03 Sep 2010 Celsion Corporation receives SBIR grant from the National Institutes of Health for heat-activated liposomal carboplatin development in Cancer
  • 03 Sep 2010 Preclinical development of heat-activated liposomal docetaxel and liposomal carboplatin is ongoing in the USA (IV)
  • 17 Jun 2008 Preclinical trials in Cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top